All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
Sign Up to like & getrecommendations! Published in 2020 at "Yonsei Medical Journal"
DOI: 10.3349/ymj.2020.61.9.762
Abstract: Purpose Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class… read more here.
Keywords: 221 atra; differentiation; aml cells; idh2 mutant ... See more keywords